ELOA: A Protein Focused on DNA Double Helix Extension and Cancer Risk

Target Name: ELOA

NCBI ID: G6924

ELOA

ELOA: A Protein Focused on DNA Double Helix Extension and Cancer Risk

ELOA (Transcription Elongation Factor B Subunit 3) is a protein that plays a crucial role in the process of transcription in the cell. It is a subunit of the transcription factor B, which is a protein that binds to DNA and helps to regulate gene expression . ELOA is composed of 1,122 amino acids and has a calculated molecular weight of 11.3 kDa.

The function of ELOA is to help to extend the DNA double helix that is formed during the process of transcription. This is done by binding to a specific DNA sequence, called the A+T-rich region, and then interacting with a protein called TF - hands, which allows the DNA to be elongated.

ELOA is expressed in almost all cell types and is highly conserved across different species. It is also highly predictive of cancer risk, with higher levels of ELOA expression being associated with a greater likelihood of developing certain types of cancer.

Due to its unique function and its association with cancer, ELOA has become a focus of interest for researchers looking for new drug targets or biomarkers. There is ongoing research into the use of small molecules, such as drugs, to inhibit the activity of ELOA and reduce its ability to promote cancer growth.

In addition to its potential as a drug target, ELOA also has potential as a biomarker for cancer. Its expression has been shown to be elevated in a variety of cancer types, including breast, ovarian, and colorectal cancers. This makes it a promising candidate for use as a diagnostic or predictive marker in cancer treatment.

ELOA is also known as TFB subunit 3 because it is a subunit of the transcription factor B, which is a protein that binds to DNA and helps to regulate gene expression. The full name of the transcription factor is complex, with different studies using different names to refer to the same protein. However, all of these names ultimately come down to the same protein, which is composed of multiple subunits, including ELOA.

The study of ELOA and its function is an active area of 鈥嬧?媟esearch, with many studies looking at its role in different aspects of gene expression and its potential as a drug or biomarker. As research continues, it is likely that the full potential of ELOA will be discovered, and its use as a drug or biomarker will continue to grow.

Protein Name: Elongin A

Functions: SIII, also known as elongin, is a general transcription elongation factor that increases the RNA polymerase II transcription elongation past template-encoded arresting sites. Subunit A is transcriptionally active and its transcription activity is strongly enhanced by binding to the dimeric complex of the SIII regulatory subunits B and C (elongin BC complex)

The "ELOA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELOA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets